NeuShen Therapeutics Raises Over $80 Million in Series B Oversubscribed Round

NeuShen Therapeutics announced on September 3 that it has completed an oversubscribed Series B financing of more than $80 million. Investors in the round included B Capital, Legend Capital, Matrix Partners China, Zhenmai Investment and Shanghai State-owned Capital Operation Leading Fund, while existing shareholder Lilly Asia Ventures also added to its stake, according to Jiemian News. The company said the proceeds will be used to expand its innovative pipeline in the central nervous system field, accelerate global clinical development of core programs, and explore treatment approaches for major unmet medical needs worldwide.